{"filing":{"accession_number":"0001395064-26-000181","cik":"0001395064","ticker":"TKPHF","company_name":"TAKEDA PHARMACEUTICAL CO LTD","form":"6-K","filing_date":"2026-06-24","report_date":null,"primary_document":"form6k-1_062426.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1395064/000139506426000181/form6k-1_062426.htm"},"events":[{"id":13337,"run_id":11842,"accession_number":"0001395064-26-000181","anchor_item_number":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The exhibit discloses results of the 150th Annual General Meeting of Shareholders held on June 24, 2026, reporting shareholder approval of five proposals: appropriation of surplus (year-end dividend of 100 JPY per share), election of eight directors (including newly elected Julie Kim and Paul Stoffels), election of three audit and supervisory committee members (including newly elected Bruce Broussard and Koichiro Kimura), election of a substitute director, and approval of director bonuses. This is a classic shareholder vote results disclosure under Item 5.07 equivalent, material to investors as it reflects governance changes and capital allocation decisions.","company_name":"TAKEDA PHARMACEUTICAL CO LTD","ticker":"TKPHF","filing_date":"2026-06-24","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":10450,"accession_number":"0001395064-26-000181","item_number":null,"item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The exhibit discloses results of the 150th Annual General Meeting of Shareholders held on June 24, 2026, reporting shareholder approval of five proposals: appropriation of surplus (year-end dividend of 100 JPY per share), election of eight directors (including newly elected Julie Kim and Paul Stoffels), election of three audit and supervisory committee members (including newly elected Bruce Broussard and Koichiro Kimura), election of a substitute director, and approval of director bonuses. This is a classic shareholder vote results disclosure under Item 5.07 equivalent, material to investors as it reflects governance changes and capital allocation decisions.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-24T10:07:50.420907+00:00","company_name":"TAKEDA PHARMACEUTICAL CO LTD","ticker":"TKPHF","filing_date":"2026-06-24"}]}